Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Sell
20
NKTR Quote, Financials, Valuation and Earnings
Last price:
$0.50
Seasonality move
:
-1.17%
Day range:
$0.43 - $0.53
52-week range:
$0.43 - $1.93
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.07x
P/B ratio:
1.56x
Volume:
3.6M
Avg. volume:
2M
1-year change:
-59.15%
Market cap:
$95M
Revenue:
$98.4M
EPS (TTM):
-$0.59
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
$15.6M | -$0.18 | -27.88% | -4.43% | $4.75 |
|
CORT
Corcept Therapeutics
|
$177.9M | $0.14 | 21.2% | -40% | $143.25 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.24 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -100% | -67.93% | $7.00 |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | $6.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
$0.51 | $4.75 | $95M | -- | $0.00 | 0% | 1.07x |
|
CORT
Corcept Therapeutics
|
$72.97 | $143.25 | $7.7B | 58.85x | $0.00 | 0% | 12.27x |
|
NBY
NovaBay Pharmaceuticals
|
$0.50 | $0.85 | $2.9M | -- | $0.00 | 0% | 0.13x |
|
OGEN
Oragenics
|
$0.19 | $1.00 | $4.1M | -- | $0.00 | 0% | 1.18x |
|
PTN
Palatin Technologies
|
$0.44 | $7.00 | $11.5M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.05 | $6.00 | $2.9M | -- | $0.00 | 0% | 0.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
-- | -1.333 | -- | 4.18x |
|
CORT
Corcept Therapeutics
|
-- | -0.943 | -- | 3.11x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.451 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | 3.461 | -- | -- |
|
PTN
Palatin Technologies
|
-- | 0.220 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -1.635 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NKTR
Nektar Therapeutics
|
$21.2M | -$24.7M | -133.07% | -133.07% | 58.8% | -$46.6M |
|
CORT
Corcept Therapeutics
|
$178.9M | $25.3M | 23.78% | 23.78% | 13.89% | $59.2M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
OGEN
Oragenics
|
-- | -$3.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
-- | -$5.1M | -- | -- | -2356.3% | -$4.8M |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
Nektar Therapeutics vs. Competitors
-
Which has Higher Returns NKTR or CORT?
Corcept Therapeutics has a net margin of 24.89% compared to Nektar Therapeutics's net margin of 16.9%. Nektar Therapeutics's return on equity of -133.07% beat Corcept Therapeutics's return on equity of 23.78%.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics72.66% $0.03 $60.7M CORTCorcept Therapeutics98.38% $0.26 $679.6M -
What do Analysts Say About NKTR or CORT?
Nektar Therapeutics has a consensus price target of $4.75, signalling upside risk potential of 830.28%. On the other hand Corcept Therapeutics has an analysts' consensus of $143.25 which suggests that it could grow by 96.31%. Given that Nektar Therapeutics has higher upside potential than Corcept Therapeutics, analysts believe Nektar Therapeutics is more attractive than Corcept Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics3 2 0 CORTCorcept Therapeutics2 0 0 -
Is NKTR or CORT More Risky?
Nektar Therapeutics has a beta of 0.686, which suggesting that the stock is 31.381% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.145, suggesting its less volatile than the S&P 500 by 85.456%.
-
Which is a Better Dividend Stock NKTR or CORT?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or CORT?
Nektar Therapeutics quarterly revenues are $29.2M, which are smaller than Corcept Therapeutics quarterly revenues of $181.9M. Nektar Therapeutics's net income of $7.3M is lower than Corcept Therapeutics's net income of $30.7M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Corcept Therapeutics's PE ratio is 58.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 1.07x versus 12.27x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics1.07x -- $29.2M $7.3M CORTCorcept Therapeutics12.27x 58.85x $181.9M $30.7M
-
Which has Higher Returns NKTR or NBY?
NovaBay Pharmaceuticals has a net margin of 24.89% compared to Nektar Therapeutics's net margin of -49.65%. Nektar Therapeutics's return on equity of -133.07% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics72.66% $0.03 $60.7M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About NKTR or NBY?
Nektar Therapeutics has a consensus price target of $4.75, signalling upside risk potential of 830.28%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 69.97%. Given that Nektar Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Nektar Therapeutics is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics3 2 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is NKTR or NBY More Risky?
Nektar Therapeutics has a beta of 0.686, which suggesting that the stock is 31.381% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.
-
Which is a Better Dividend Stock NKTR or NBY?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or NBY?
Nektar Therapeutics quarterly revenues are $29.2M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Nektar Therapeutics's net income of $7.3M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 1.07x versus 0.13x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics1.07x -- $29.2M $7.3M NBYNovaBay Pharmaceuticals0.13x -- $2.4M -$1.2M
-
Which has Higher Returns NKTR or OGEN?
Oragenics has a net margin of 24.89% compared to Nektar Therapeutics's net margin of --. Nektar Therapeutics's return on equity of -133.07% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics72.66% $0.03 $60.7M OGENOragenics-- -$0.27 -- -
What do Analysts Say About NKTR or OGEN?
Nektar Therapeutics has a consensus price target of $4.75, signalling upside risk potential of 830.28%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 426.32%. Given that Nektar Therapeutics has higher upside potential than Oragenics, analysts believe Nektar Therapeutics is more attractive than Oragenics.
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics3 2 0 OGENOragenics0 1 0 -
Is NKTR or OGEN More Risky?
Nektar Therapeutics has a beta of 0.686, which suggesting that the stock is 31.381% less volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.
-
Which is a Better Dividend Stock NKTR or OGEN?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or OGEN?
Nektar Therapeutics quarterly revenues are $29.2M, which are larger than Oragenics quarterly revenues of --. Nektar Therapeutics's net income of $7.3M is higher than Oragenics's net income of -$3.3M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 1.07x versus 1.18x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics1.07x -- $29.2M $7.3M OGENOragenics1.18x -- -- -$3.3M
-
Which has Higher Returns NKTR or PTN?
Palatin Technologies has a net margin of 24.89% compared to Nektar Therapeutics's net margin of -2357.27%. Nektar Therapeutics's return on equity of -133.07% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics72.66% $0.03 $60.7M PTNPalatin Technologies-- -$0.12 -$111.5K -
What do Analysts Say About NKTR or PTN?
Nektar Therapeutics has a consensus price target of $4.75, signalling upside risk potential of 830.28%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1483.71%. Given that Palatin Technologies has higher upside potential than Nektar Therapeutics, analysts believe Palatin Technologies is more attractive than Nektar Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics3 2 0 PTNPalatin Technologies0 0 0 -
Is NKTR or PTN More Risky?
Nektar Therapeutics has a beta of 0.686, which suggesting that the stock is 31.381% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.
-
Which is a Better Dividend Stock NKTR or PTN?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or PTN?
Nektar Therapeutics quarterly revenues are $29.2M, which are larger than Palatin Technologies quarterly revenues of $350K. Nektar Therapeutics's net income of $7.3M is higher than Palatin Technologies's net income of -$2.4M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 1.07x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics1.07x -- $29.2M $7.3M PTNPalatin Technologies-- -- $350K -$2.4M
-
Which has Higher Returns NKTR or TOVX?
Theriva Biologics has a net margin of 24.89% compared to Nektar Therapeutics's net margin of --. Nektar Therapeutics's return on equity of -133.07% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NKTRNektar Therapeutics72.66% $0.03 $60.7M TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About NKTR or TOVX?
Nektar Therapeutics has a consensus price target of $4.75, signalling upside risk potential of 830.28%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 471.43%. Given that Nektar Therapeutics has higher upside potential than Theriva Biologics, analysts believe Nektar Therapeutics is more attractive than Theriva Biologics.
Company Buy Ratings Hold Ratings Sell Ratings NKTRNektar Therapeutics3 2 0 TOVXTheriva Biologics0 0 0 -
Is NKTR or TOVX More Risky?
Nektar Therapeutics has a beta of 0.686, which suggesting that the stock is 31.381% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.
-
Which is a Better Dividend Stock NKTR or TOVX?
Nektar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nektar Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NKTR or TOVX?
Nektar Therapeutics quarterly revenues are $29.2M, which are larger than Theriva Biologics quarterly revenues of --. Nektar Therapeutics's net income of $7.3M is higher than Theriva Biologics's net income of -$4.4M. Notably, Nektar Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nektar Therapeutics is 1.07x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NKTRNektar Therapeutics1.07x -- $29.2M $7.3M TOVXTheriva Biologics0.63x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Archer Aviation a Buy, Sell or Hold?
Vertical takeoff and landing (eVTOL) aircraft sound futuristic but that’s…
Down 50%, Is Dell Technologies a Buy?
Dell (NYSE:DELL)’s share price has been on a roller coaster…
Stock Ideas
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
33
BULZ alert for Apr 10
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 15.35% over the past day.
Sell
31
TECS alert for Apr 10
Direxion Daily Technology Bear 3x Shares [TECS] is up 12.66% over the past day.
Sell
48
FNGA alert for Apr 10
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 13.3% over the past day.
